Ultragenyx, Kyowa Kirin announce Health Canada approval for Crysvita

Ultragenyx, Kyowa Kirin announce Health Canada approval for Crysvita  Ultragenyx, Kyowa Kirin and Kyowa Kirin International announced that Crysvita has been approved by Health Canada for the treatment of X-linked hypophosphatemia, or XLH, in adult and pediatric patients one year of age and older. The product is expected to be available for prescription to Canadian patients in early 2019. XLH is a hereditary, lifelong disease.
https://thefly.com/landingPageNews.php?id=2832975